AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns
JPMorgan views AbbVie's recent 12% stock pullback as a buying opportunity, reiterating an Overweight rating and a $260 price target. Despite competitive pressures and a significant R&D charge, the firm sees upside driven by strong growth in Skyrizi and Rinvoq, which now surpass Humira's peak sales. The analyst consensus remains bullish with 22 buy ratings, supported by AbbVie's immunology and neuroscience segment growth and a 3.18% dividend yield.
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
Allergan Aesthetics, an AbbVie company, announced the opening of its third U.S. AMI Training Center in Austin, Texas, expanding its national training network for healthcare professionals. This new state-of-the-art facility provides comprehensive, hands-on education focusing on advanced injection techniques, complication management, and practice development across Allergan Aesthetics' portfolio. The center aims to elevate aesthetics education standards, improve patient care, and support practitioners' professional growth through an immersive learning experience.
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
Allergan Aesthetics has opened its third U.S. Allergan Medical Institute (AMI) training center in Austin, Texas, on April 7, 2026. This state-of-the-art facility will provide healthcare professionals with hands-on education in facial injectables, body contouring, skincare, and regenerative medicine, reinforcing Allergan's commitment to advancing aesthetic education. The center, directed by Dr. Saami Khalifian, aims to enhance clinical proficiency, complication management, and practice development for providers.
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
Halozyme Therapeutics, Inc. has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon™ technology. This microparticle technology aims to reduce drug injection volumes, enabling more convenient at-home administration. The agreement includes a $15 million upfront payment to Halozyme, with potential for future milestone payments and royalties on net sales of developed products.
69,065 Shares in AbbVie Inc. $ABBV Acquired by Robinhood Asset Management LLC
Robinhood Asset Management LLC has acquired 69,065 shares of AbbVie Inc. ($ABBV) during the fourth quarter, representing a stake valued at approximately $15.78 million and making AbbVie its 18th largest holding. This acquisition comes despite AbbVie cutting its Q1 and FY2026 guidance due to a significant R&D charge, which has caused recent negative price action. The company also declared a quarterly dividend of $1.73, offering a 3.3% yield, though its dividend payout ratio is notably high.
J.P. Morgan Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $260
J.P. Morgan has reiterated its Buy rating for AbbVie (ABBV.US) and maintained its target price at $260. This indicates the firm's continued positive outlook on the pharmaceutical company's stock performance.
TrumpRx adds medicines from AbbVie and Roche (ABBV:NYSE)
AbbVie (ABBV) and Roche's (RHHBY) Genentech unit have joined TrumpRx, a government-run direct-to-consumer platform, making their medicines available through the service. This development was reported by CBS News and signifies a continued expansion of the TrumpRx platform.
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook
Biogen has expanded its neurology and rare disease portfolio by acquiring Apellis Pharmaceuticals and securing FDA approval for a high-dose regimen of SPINRAZA for spinal muscular atrophy. These strategic moves aim to diversify Biogen's pipeline and revenue streams, particularly within the growing market for rare disease and specialty medicines. Investors will be closely watching the integration of Apellis' assets and the adoption rate of the new SPINRAZA regimen to assess their impact on the company's financial performance.
AbbVie Inc. $ABBV Shares Sold by Sound Income Strategies LLC
Sound Income Strategies LLC has reduced its stake in AbbVie Inc. (ABBV) by 8.3%, selling 8,649 shares, leaving them with 95,984 shares valued at $20.57 million. This comes as AbbVie lowered its Q1 and full-year 2026 earnings outlook due to a $744 million R&D charge, contributing to recent share weakness. Insider selling has also been reported, with two executives selling significant numbers of shares.
Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals
Regeneron Pharmaceuticals (REGN) is under valuation scrutiny after the FDA approved extended dosing for EYLEA HD, easing treatment schedules. Despite a 34% one-year total shareholder return, the stock's year-to-date performance is slightly negative. Simply Wall St's analysis suggests REGN is modestly undervalued at $763.04, with a fair value pegged at $873.78, though its P/E ratio is higher than the US Biotech average.
AbbVie Inc. $ABBV Stake Lowered by Albion Financial Group UT
Albion Financial Group UT significantly reduced its stake in AbbVie Inc. by 47.9% in Q4, selling 22,007 shares. Despite AbbVie beating Q4 earnings and revenue estimates, the stock was impacted by a trimmed Q1 and full-year outlook due to a $744M R&D charge. The company announced a quarterly dividend of $1.73, while institutional ownership stands at approximately 70% with analysts maintaining a "Moderate Buy" rating and a target price of $253.15.
Albion Financial Group UT Trims AbbVie Inc. Stake
Albion Financial Group UT has significantly reduced its stake in AbbVie Inc. by 47.9% in the fourth quarter, selling 22,007 shares. The institutional investor now holds 23,971 shares valued at $5,477,000. This move suggests potential concerns about AbbVie's future performance and could indicate a broader shift in market sentiment.
AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Analysts
AbbVie Inc. (NYSE:ABBV) has an average "Moderate Buy" rating from analysts, with a 12-month average price target of $253.15, despite recent earnings weakness due to a $744M R&D charge. The company reported Q4 EPS of $2.71 on $16.62 billion revenue and offers an annualized dividend of $6.92, yielding about 3.3%. Institutional investors hold a significant portion of its stock, with recent insider selling noted.
AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge
AbbVie lowered its earnings outlook for both Q1 and the full fiscal year 2026. This adjustment follows a significant $744 million research and development charge the company incurred. The R&D charge is likely related to a specific project or pipeline asset that did not meet expectations.
Healthcare, Financials ETFs Get A Mega-Cap Reset With TRUF, TRUH
VanEck has launched two new TruSector ETFs, TRUF (Financials) and TRUH (Healthcare), designed to provide more precise and less diluted exposure to mega-cap leaders within their respective sectors. These ETFs aim to address the diversification constraints of traditional sector ETFs under RIC rules, allowing for meaningful allocations to dominant companies. Both funds feature a competitive expense ratio of 0.10% and maintain compliance while striving for cleaner sector representation and reduced tracking error.
Mckesson Corp Stock (MCK) Closed Down by 3.20% on Apr 6: Key Drivers Unveiled
McKesson Corp (MCK) stock closed down 3.20% on April 6, primarily due to B of A Securities lowering its price target and recent insider selling activity. Additionally, major institutional investors like UBS and T. Rowe Price reduced their holdings in the previous quarter. Despite these pressures, McKesson reported strong Q3 FY2026 results and raised full-year EPS guidance, indicating the decline was not due to operational performance.
AbbVie Inc. stock underperforms Monday when compared to competitors
AbbVie Inc. (ABBV) stock fell by 1.03% to $206.69 on Monday, underperforming the broader market as both the S&P 500 Index and Dow Jones Industrial Average saw gains. This marked the third consecutive day of losses for the company's shares.
Parkinson’s Disease Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics
DelveInsight's "Parkinson’s Disease Pipeline Insight, 2026" report outlines the current clinical development landscape for Parkinson's Disease, highlighting over 80 companies and 100+ therapies in various stages of development. The report details emerging therapies, their mechanisms of action, clinical study updates, and factors influencing the market. Recent advancements include new FDA approvals, promising stem cell therapies, and the progression of several drugs into late-stage clinical trials, alongside some discontinuations.
9 Newly Overvalued Stocks this Week
Morningstar identifies nine US-listed stocks that have recently become overvalued, warranting 1- or 2-star ratings. The list includes AbbVie, BHP Group, Mizuho Financial Group, CSX, Sempra, Vulcan Materials, Vodafone Group, MasTec, and Ralph Lauren, with detailed metrics for each. This analysis is based on Morningstar's proprietary rating system, which considers stock price, fair value estimate, and uncertainty rating.
Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
Scotiabank has reiterated its Buy rating for AbbVie (ABBV.US) and maintained its target price at $280. This indicates a continued positive outlook on the biopharmaceutical company's stock by the financial institution.
Gilead Has Fallen 11% From Its 52-Week High. Is Now the Time to Buy GILD?
Gilead Sciences (GILD) stock has dropped 11% from its 52-week high, prompting investors to question if this presents a buying opportunity. The company recently made two major acquisitions, with the primary deal acquiring Arcellx for its CAR T-cell therapy anito-cel, awaiting FDA approval. Despite an expanded balance sheet, a strong HIV franchise, and multiple upcoming commercial launches targeted for 2026, the company faces risks like potential delays in drug approvals and impacts from the Inflation Reduction Act on Biktarvy's revenue.
Schwab U.S. Dividend Equity ETF Holdings & Sector Changes 2026 - News and Statistics
The Schwab U.S. Dividend Equity ETF recently reconstituted its holdings, adding 25 new stocks like UnitedHealth Group, Procter & Gamble, and Abbott Laboratories, while removing 22, including AbbVie, Cisco Systems, and Valero. These adjustments led to increased exposure in healthcare and technology sectors and a substantial decrease in energy and materials. The ETF aims to provide passive income through dividends and uses specific criteria for stock selection.
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?
AbbVie is set to report its first-quarter 2026 results, with investor attention focused on its immunology segment, particularly the performance of Skyrizi and Rinvoq. These drugs are crucial for driving growth following the loss of exclusivity for Humira. While Skyrizi and Rinvoq sales are expected to show strong growth, Humira sales are projected to decline significantly, and AbbVie faces increasing competition in the immunology market from companies like Johnson & Johnson and Eli Lilly.
AbbVie Lowers 2026 Earnings Guidance Amid Expenses
AbbVie (ABBV) has lowered its Q1 and full-year 2026 earnings guidance due to $744 million in pre-tax expenses related to acquired in-process R&D, impacting earnings by $0.41 per share. The revised full-year adjusted diluted EPS is projected at $13.96 to $14.16, falling below consensus estimates. This announcement led to a 2.86% drop in AbbVie's shares on Monday, reflecting market concerns about its financial outlook.
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Neurocrine Biosciences has announced its definitive agreement to acquire Soleno Therapeutics for $2.9 billion, or $53.00 per share in cash. This acquisition will add VYKAT XR, a first-in-class treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio, enhancing its leadership in endocrinology and rare diseases. The deal is expected to accelerate revenue growth, diversify Neurocrine's offerings, and leverage VYKAT XR's strong intellectual property, which extends into the mid-2040s.
Sowell Financial Services LLC Has $10.85 Million Position in AbbVie Inc. $ABBV
Sowell Financial Services LLC reduced its stake in AbbVie Inc. by 10.8% in the fourth quarter, selling 5,761 shares and ending with holdings valued at approximately $10.85 million. Despite insider sales totaling over $6 million, institutional investors own 70.23% of the stock. Analysts maintain a "Moderate Buy" consensus with an average target price of $253.15, while AbbVie recently beat Q4 EPS estimates and declared a $1.73 quarterly dividend.
AbbVie forecasts $744M hit from drug pipeline costs
AbbVie anticipates a $744 million impact from drug pipeline costs. This information was reported on April 6, 2026, by Jon Asplund for Crain's Chicago Business. The article title is the only information provided about the content.
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
This article analyzes the Q4 earnings of Myriad Genetics (NASDAQ:MYGN) and compares its performance with other therapeutics stocks. While the therapeutics sector saw strong revenue beats collectively, individual stock performances varied. Myriad Genetics exceeded expectations with flat year-on-year revenue and strong full-year EBITDA guidance, showcasing positive momentum in key testing areas.
Anal Fissure Treatment Market Set to Boom Rapidly by 2033 |Abvie, Novartis AG, Teva Pharmaceuticals, Troikaa
The Anal Fissure Treatment Market is projected to grow from USD 1,152.1 million in 2025 to USD 1,653.8 million in 2032, exhibiting a CAGR of 5.3%. A new report by Coherent Market Insights provides key insights into market structure, strategic hot spots, and competitive landscapes, featuring major players like Abvie, Novartis AG, and Teva Pharmaceuticals. The study segments the market by treatment type, route of administration, and distribution channel, offering guidance for strategic decision-making.
Pleural Diseases Market Set to Boom Rapidly by 2033 |Bristol Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc
The global Pleural Diseases Market is projected to grow from USD 5.76 billion in 2025 to USD 9.37 billion in 2032, exhibiting a CAGR of 7.2%. This growth is driven by rapid innovation and shifting regional dynamics, with key players including Bristol Myers Squibb, Merck & Co., Inc., and GlaxoSmithKline plc. The market is segmented by disease type, diagnostic tools, treatment modalities, and end-users, and the report provides strategic insights for stakeholders.
Antibodies Market To Witness Substantial Growth, 2026-2033 | Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc.
The Antibodies Market is projected to experience substantial growth,
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
This article analyzes the Q4 earnings across various therapeutics stocks, spotlighting Myriad Genetics' performance relative to its peers. Myriad Genetics (MYGN) exceeded analyst expectations with flat year-on-year revenue but strong full-year EBITDA guidance, driven by growth in cancer and mental health testing. The piece also reviews the results of Novavax (NVAX), United Therapeutics (UTHR), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV), highlighting their revenue performance, market reactions, and key business developments.
Precigen (PGEN) Is Up 7.4% After Surging Revenue And Wider 2025 Losses Are Reported – Has The Bull Case Changed?
Precigen (PGEN) experienced a 7.4% stock increase after reporting a significant rise in 2025 revenue to US$9.68 million, alongside a widened net loss of US$250.64 million. This article examines how these results, particularly the substantial net loss, impact the investment outlook for Precigen and its primary therapy, PAPZIMEOS. While revenue growth is encouraging, the increased losses highlight the importance of successful commercialization and raise concerns about short-term dilution and financing risks.
AbbVie Inc. $ABBV Shares Purchased by Kelleher Financial Advisors
Kelleher Financial Advisors significantly increased its stake in AbbVie Inc. (NYSE:ABBV) during Q4, now holding 11,903 shares valued at $2.72 million. Despite this, company insiders, including EVP Perry C. Siatis and SVP David Ryan Purdue, have recently sold a substantial number of shares. AbbVie beat Q4 earnings estimates, provided strong FY2026 guidance, and announced a $1.73 quarterly dividend, maintaining a "Moderate Buy" consensus rating among analysts.
Savvy Advisors Inc. Buys 6,646 Shares of AbbVie Inc. $ABBV
Savvy Advisors Inc. increased its stake in AbbVie Inc. by 22.2% during the fourth quarter, purchasing 6,646 additional shares to bring its total holdings to 36,568 shares valued at approximately $8.355 million. Meanwhile, several AbbVie executives, including SVP David Ryan Purdue and EVP Perry C. Siatis, sold significant portions of their shares. Analysts maintain a "Moderate Buy" rating for AbbVie, with a consensus target price of $253.15, following the company's strong Q4 earnings beat and optimistic FY2026 guidance.
AbbVie Inc. $ABBV Shares Purchased by JB Capital LLC
JB Capital LLC increased its stake in AbbVie Inc. (NYSE:ABBV) by 269.7% in Q4, owning 16,913 shares valued at $3.86 million. AbbVie reported strong Q4 earnings, beating analyst estimates with $2.71 EPS and $16.62 billion in revenue, and issued positive FY2026 guidance. The company declared a quarterly dividend of $1.73 per share, representing an annualized yield of 3.3%.
AbbVie Inc. (ABBV) stock price, news, quote and history
This article provides a comprehensive overview of AbbVie Inc. (ABBV) stock, including its current price, historical data, financial performance, and analyst insights. It details the company's diverse portfolio of pharmaceutical products and therapeutic areas, along with a comparison to other major drug manufacturers. The stock's performance metrics, earnings trends, and key valuation measures are also presented.
AbbVie Inc. $ABBV is Advocate Group LLC's 4th Largest Position
Advocate Group LLC has made AbbVie Inc. (ABBV) its 4th largest holding, despite trimming its stake by 7.3%, owning 76,212 shares valued at $17.41 million. AbbVie recently reported strong Q4 results, surpassing EPS and revenue estimates, and announced a quarterly dividend of $1.73 per share. However, the article also notes significant insider sales and a high dividend payout ratio.
BGIG ETF Volume Surges 11x as Johnson & Johnson Shines
The Bahl & Gaynor Income Growth ETF (BGIG) has experienced an 11x surge in trading volume. This heightened activity is linked to key holdings like Johnson & Johnson, which received fresh analyst attention (J.P. Morgan reiterated a Hold rating), and Microsoft, which is performing strongly with its Copilot AI tools. Broadcom faced a downgrade due to software growth concerns, while Eli Lilly and AbbVie moved forward with clinical studies, and Taiwan Semiconductor Manufacturing saw share price increases due to AI chip demand.
AbbVie (MIL:1ABBV) PB Ratio : (As of Apr. 04, 2026)
This article analyzes AbbVie's Price-to-Book (PB) Ratio as of April 4, 2026. It defines the PB Ratio, presents AbbVie's current PB Ratio of €185.60 / €-1.58, and provides historical data and industry comparisons. The article also notes that GuruFocus considers AbbVie's stock to be overvalued based on its GF Value.
AbbVie Inc. $ABBV Shares Bought by SteelPeak Wealth LLC
SteelPeak Wealth LLC increased its stake in AbbVie Inc. by 58.6% in the fourth quarter, purchasing an additional 15,135 shares and bringing their total holdings to $9.36 million. Other institutional investors like Vanguard Group Inc., Legal & General Group Plc, and Wellington Management Group LLP also modified their positions. The article also provides financial details, recent earnings, dividend information, and analyst ratings for AbbVie.
Thurston Springer Miller Herd & Titak Inc. Acquires 6,946 Shares of AbbVie Inc. $ABBV
Thurston Springer Miller Herd & Titak Inc. significantly increased its stake in AbbVie Inc. by 966.1% in Q4, acquiring an additional 6,946 shares to hold 7,665 shares valued at $1.752 million. This comes alongside recent insider selling by two executives, Perry C. Siatis and David Ryan Purdue, who reduced their positions by 36.98% and 66.34% respectively. AbbVie, which beat Q4 EPS estimates and provided strong FY2026 guidance, maintains a "Moderate Buy" consensus rating and offers a 3.3% dividend yield.
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Sells 8,610 Shares of AbbVie Inc. $ABBV
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors reduced its stake in AbbVie Inc. by 29.8% in Q4, selling 8,610 shares and retaining 20,322 shares valued at $4.643 million. This comes as company insiders also sold significant portions of their holdings. AbbVie reported strong Q4 earnings, surpassing estimates, and declared a quarterly dividend of $1.73 per share, representing a 3.3% yield.
C2P Capital Advisory Group Trims AbbVie Stake
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors has reduced its stake in AbbVie Inc. by nearly 30% during the fourth quarter, selling 8,610 shares. The firm now holds 20,322 shares of AbbVie, valued at $4.6 million. This move provides insight into their investment strategies and potential market outlook shifts.
AbbVie & Amgen: Safe Dividend Stocks for Recession Fears | 2026 - News and Statistics
Amidst growing recession fears and a volatile market, investors are seeking stability, leading to a focus on healthcare sector stocks like AbbVie and Amgen. AbbVie, a pharmaceutical company with strong portfolios in immunology, oncology, and neuroscience, is considered a safe bet due to its critical treatments and status as a Dividend King. Amgen, despite recent patent expirations, maintains business stability with a broad portfolio and promising pipeline, making both companies attractive for risk-averse investors.
AbbVie reports $744 million IPR&D expense for Q1, updates 2026 earnings guidance
AbbVie announced that its preliminary first quarter 2026 results are expected to include a $744 million pre-tax expense for acquired in-process research and development (IPR&D) and milestones. This will unfavorably impact both GAAP and non-GAAP diluted earnings per share by $0.41. Consequently, the company has updated its adjusted diluted earnings per share guidance for 2026 to a range of $13.96 to $14.16, incorporating this expense.
AbbVie Posts Record $61B Revenue as Skyrizi and Rinvoq Surge Past Peak Humira Sales
AbbVie achieved a record $61.2 billion in net revenues, largely driven by the strong performance of its immunology drugs, Skyrizi and Rinvoq, which have surpassed the peak sales of Humira. Positive Phase 3 results for Skyrizi's subcutaneous formulation and its significant market share in inflammatory bowel disease indicate continued growth. With a high-single-digit revenue growth projection through at least 2029 and a robust pipeline, AbbVie's stock is considered undervalued by TIKR's models.
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
Regeneron Pharmaceuticals (NASDAQ: REGN) is undergoing a significant transformation, moving beyond its core immunology and ophthalmology franchises to aggressively enter the oncology and obesity markets. The company, known for its science-first approach and internal innovation, is navigating the challenges of biosimilar competition and shifting regulatory landscapes while leveraging its robust R&D and strong balance sheet for future growth. Key catalysts include upcoming data readouts for Fianlimab in oncology and advancements in its obesity and gene therapy programs.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month price target of $20.29. Despite beating recent earnings and revenue estimates, the company remains unprofitable. Institutional investors own nearly 95% of the stock, which is currently trading around $13.14.
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner
Viking Therapeutics (VKTX) stock rose over 2% after CNBC's Fast Money suggested it could be a buyout target this year as big pharma companies compete in the rapidly expanding GLP-1 obesity market. Traders noted that acquisitions are a primary strategy for drugmakers to secure advanced weight-loss therapy pipelines, with Viking's experimental obesity therapy VK2735 advancing through Phase 3 trials and planned late-stage testing for its oral formulation. Investor sentiment on Stocktwits for VKTX has shifted to 'neutral' from 'bullish' amidst a significant increase in message volume.
